Merck launches health reference tome

Share this article:
Merck launches health reference tome
Merck launches health reference tome
Merck's nonprofit publishing arm launched a 2,500-page health reference book for consumers, available in hardcover or via iPhone app.

The book, titled The Merck Manual Home Health Handbook, was launched in response to survey data showing that 64% of consumers named physicians as their most trusted source of health information. The Merck reference book is authored by “300 key worldwide medical experts,” according to a statement. The book costs $28.76 at Amazon.com.

The iPhone app, developed in collaboration with app-developer Agile Partners and available through the iTunes store for $9.99, offers the same content as the hardback edition. Users of the app can share health topics via email and bookmark favorite subjects, the statement said.

“In addition to the latest health care and medical information, we included a practical ‘emergencies and injuries' section that is accessible from the app home screen,” said Robert Porter, editor-in-chief of The Merck Manuals, in the statement.

Merck concurrently launched a professional version of the app for doctors and nurses. That version costs $29.99, and features information on symptoms, text searches, and a bookmarking system that records a history of topics viewed by a physician.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.